2 型糖尿病患者使用钠-葡萄糖共转运体 2 抑制剂比使用二肽基肽酶-4 抑制剂的心房颤动风险更低：一项全国队列研究

IF 3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Korean Circulation Journal Pub Date : 2024-03-13 DOI:10.4070/kcj.2023.0234

Min Kim, Kyoung Hwa Ha, Junyoung Lee, Sangshin Park, Kyeong Seok Oh, Dae-Hwan Bae, Ju Hee Lee, Sang Min Kim, Woong Gil Choi, Kyung-Kuk Hwang, Dong-Woon Kim, Myeong-Chan Cho, Dae Jung Kim, Jang-Whan Bae

{"title":"2 型糖尿病患者使用钠-葡萄糖共转运体 2 抑制剂比使用二肽基肽酶-4 抑制剂的心房颤动风险更低：一项全国队列研究","authors":"Min Kim, Kyoung Hwa Ha, Junyoung Lee, Sangshin Park, Kyeong Seok Oh, Dae-Hwan Bae, Ju Hee Lee, Sang Min Kim, Woong Gil Choi, Kyung-Kuk Hwang, Dong-Woon Kim, Myeong-Chan Cho, Dae Jung Kim, Jang-Whan Bae","doi":"10.4070/kcj.2023.0234","DOIUrl":null,"url":null,"abstract":"Accumulating evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce adverse cardiovascular outcomes. However, whether SGLT2i, compared with other antidiabetic drugs, reduce the new development of atrial fibrillation (AF) is unclear. In this study, we compared SGLT2i with dipeptidyl peptidase-4 inhibitors (DPP-4is) in terms of reduction in the risk of AF in individuals with type 2 diabetes.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":"24 1","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study.\",\"authors\":\"Min Kim, Kyoung Hwa Ha, Junyoung Lee, Sangshin Park, Kyeong Seok Oh, Dae-Hwan Bae, Ju Hee Lee, Sang Min Kim, Woong Gil Choi, Kyung-Kuk Hwang, Dong-Woon Kim, Myeong-Chan Cho, Dae Jung Kim, Jang-Whan Bae\",\"doi\":\"10.4070/kcj.2023.0234\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Accumulating evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce adverse cardiovascular outcomes. However, whether SGLT2i, compared with other antidiabetic drugs, reduce the new development of atrial fibrillation (AF) is unclear. In this study, we compared SGLT2i with dipeptidyl peptidase-4 inhibitors (DPP-4is) in terms of reduction in the risk of AF in individuals with type 2 diabetes.\",\"PeriodicalId\":17850,\"journal\":{\"name\":\"Korean Circulation Journal\",\"volume\":\"24 1\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-03-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Korean Circulation Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4070/kcj.2023.0234\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Circulation Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4070/kcj.2023.0234","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

越来越多的证据表明，钠-葡萄糖共转运体 2 抑制剂（SGLT2i）可减少不良心血管后果。然而，与其他抗糖尿病药物相比，SGLT2i 是否能降低心房颤动（房颤）的新发病率尚不清楚。在这项研究中，我们比较了 SGLT2i 和二肽基肽酶-4 抑制剂（DPP-4is）在降低 2 型糖尿病患者房颤风险方面的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2 Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study.

Accumulating evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce adverse cardiovascular outcomes. However, whether SGLT2i, compared with other antidiabetic drugs, reduce the new development of atrial fibrillation (AF) is unclear. In this study, we compared SGLT2i with dipeptidyl peptidase-4 inhibitors (DPP-4is) in terms of reduction in the risk of AF in individuals with type 2 diabetes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Korean Circulation Journal CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

4.90

自引率

17.20%

发文量

103

期刊介绍： Korean Circulation Journal is the official journal of the Korean Society of Cardiology, the Korean Pediatric Heart Society, the Korean Society of Interventional Cardiology, and the Korean Society of Heart Failure. Abbreviated title is ''Korean Circ J''. Korean Circulation Journal, established in 1971, is a professional, peer-reviewed journal covering all aspects of cardiovascular medicine, including original articles of basic research and clinical findings, review articles, editorials, images in cardiovascular medicine, and letters to the editor. Korean Circulation Journal is published monthly in English and publishes scientific and state-of-the-art clinical articles aimed at improving human health in general and contributing to the treatment and prevention of cardiovascular diseases in particular. The journal is published on the official website (https://e-kcj.org). It is indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, Web of Science), Scopus, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, KoreaMed, KoreaMed Synapse and KoMCI, and easily available to wide international researchers